School of Management, Chongqing Jiaotong University, No.66 Xuefu Road, Nan'an District, Chongqing 400074, China.
Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):157-69. doi: 10.1586/14737167.2015.963557. Epub 2014 Oct 28.
Pharmaceutical expenditure is rising by 16% per annum in China and is now 46% of total expenditure. Initiatives to moderate growth include drug pricing regulations and encouraging international non-proprietary name prescribing. However, there is no monitoring of physician prescribing quality and perverse incentives.
Assess changes in angiotensin receptor blocker (ARB) utilization and expenditure as more generics become available; compare findings to Europe.
Observational retrospective study of ARB utilization and expenditure between 2006 and 2012 in the largest hospital in Chongqing district.
Variable and low use of generics versus originators with a maximum of 31% among single ARBs. Similar for fixed dose combinations. Prices typically reduced over time, greatest for generic telmisartan (-54%), mirroring price reductions in some European countries. However, no preferential increase in prescribing of lower cost generics. Accumulated savings of 33 million CNY for this large provider if they adopted European practices.
Considerable opportunities to improve prescribing efficiency in China.
中国的药品支出正以每年 16%的速度增长，目前占总支出的 46%。为了控制增长，已经采取了药品定价管制和鼓励使用国际非专利名等措施。然而，目前还没有对医生处方质量进行监测，也没有消除不当激励。
评估随着更多仿制药的出现，血管紧张素受体阻滞剂（ARB）的使用和支出的变化；并与欧洲进行比较。
对重庆地区最大医院 2006 年至 2012 年 ARB 的使用和支出进行观察性回顾性研究。
与原研药相比，仿制药的使用和支出存在差异且较低，单一 ARB 的仿制药最高使用率为 31%。固定剂量复方制剂也类似。价格通常随着时间的推移而降低，其中替米沙坦的仿制药降幅最大（-54%），反映了一些欧洲国家的价格降低情况。然而，并没有优先增加开处方使用成本较低的仿制药。如果采用欧洲的做法，这家大型医疗机构可节省 3300 万元人民币。
中国在提高处方效率方面有很大的机会。
